Lercanidipine Hcl Sandoz

Lercanidipine hydrochloride, the active ingredient in Lercanidipine Hcl Sandoz, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adult patients diagnosed with hypertension, helping to reduce cardiovascular risk.

GNH USA supplies Lercanidipine Hcl Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with consistent quality and regulatory adherence. The product meets EU market standards and is manufactured under strict Good Manufacturing Practice, ensuring reliability for diverse therapeutic needs.

Lercanidipine is a calcium channel blocker indicated for the management of hypertension.

- Essential hypertension: reduces both systolic and diastolic blood pressure in patients with primary high blood pressure. - Isolated systolic hypertension: helps lower elevated systolic pressure, particularly in older adults. - Hypertensive patients with cardiovascular risk: contributes to overall risk reduction by improving vascular tone.

Adverse reactions may occur with Lercanidipine therapy. Patients should be aware of both common and serious possibilities.

Common Side Effects: - Headache: mild to moderate pain often occurring shortly after dose initiation. - Peripheral edema: swelling of ankles or lower limbs due to fluid accumulation. - Flushing: transient warmth and redness of the skin. - Dizziness: sensation of light‑headedness, especially when standing quickly.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure that may cause fainting. - Angioedema: rapid swelling of face, lips, tongue, or throat requiring immediate medical attention. - Myocardial infarction: rare occurrence of heart attack symptoms. - Significant liver enzyme elevation: abnormal liver function tests indicating possible hepatic injury.

Before initiating therapy, clinicians should consider several safety aspects.

- Cardiovascular assessment: evaluate for existing heart failure or unstable angina. - Renal function: adjust use in patients with severe renal impairment. - Hepatic function: monitor liver enzymes in patients with known liver disease. - Concomitant antihypertensives: avoid excessive blood pressure reduction when combined with other agents. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture and direct sunlight.

Lercanidipine may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma concentrations. - Grapefruit juice: may elevate drug levels and heighten hypotensive effects. - Simultaneous use with other calcium channel blockers: risk of additive vasodilation and severe hypotension.

Moderate Interactions (Monitor Closely):\n- Diuretics: may enhance blood pressure‑lowering effect, necessitating dose adjustments. - Beta‑blockers: combined therapy may require monitoring for bradycardia or excessive blood pressure reduction.